Merck KGaA Reports Results from the P-III (MANEUVER) Study of Pimicotinib for Treating Tenosynovial Giant Cell Tumor (TGCT)
Shots:
- The P-III (MANEUVER) study evaluates pimicotinib (50mg, QD, oral) vs PBO in TGCT patients (n=94) eligible for systemic therapy without prior anti-CSF-1/CSF-1R treatment in part 1 for 24wks. Eligible patients can enter open-label parts 2 & 3 for extended treatment & follow-up
- Trial achieved its 1EP, showing a significant ORR improvement of 54.0% vs 3.2% at wk.25 and improvements in 2EPs of stiffness (NRS: -3.00 vs -0.57) & pain (BPI: -2.32 vs 0.23). Full data will be highlighted future conferences
- Pimicotinib is a selective CSF-1R inhibitor developed by Abbisko. In Dec 2023, Abbisko partnered with Merck for exclusive commercialization in Chinese mainland, Hong Kong, Macau & Taiwan, with an option to expand globally, incl. the US
Ref: Merck | Image: Merck
Related News:- Merck KGaA Reports the Acquisition of Mirus Bio, Strengthening Upstream Portfolio
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
